New Anti-cancer Small Molecules

Small Molecule Compounds

Phoenix offers 20 anti-cancer small molecules with competitive prices and purities

Catalog Number	Product Name	Synonym	Function	Standard Size	Price
410-01	ARQ-197	Tivantinib	Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.	5 mg	$245
410-02	Axitinib	AG-013736	Axitinib inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).	25 mg	$40
410-03	BEZ235	NVP-BEZ235	BEZ235 inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.	10 mg	$40
410-04	Bosutinib	SKI-606	SKI-606 inhibited migration of breast cancer cell lines	25 mg	$38
410-05	Canertinib	CI-1033 PD-183805	Canertinib is a pan-erbB tyrosine kinase inhibitor.	5 mg	$160
410-06	CP-690550	Tasocitinib	The somatic activating janus kinase 2 mutation (JAK2)V617F is detectable in most patients with polycythemia vera (PV).	10 mg	$72
410-07	Imatinib	Gleevec CGP57148B STI571	A reversible tyrosine kinase inhibitor effective in treatment of chronic myelogenous leukemia(CML), gastrointestinal stromal tumors, eosinophilic disorders, and systemic mast cell disease.	100 mg	$30
410-08	Lapatinib	Tykerb GW572016	Lapatinib was found to have IC50 values against purified EGFR and HER2 of 10.2 and 9.8 nM, respectively, and IC50 > 10000nM against c-Raf-1, MEK, ERK, CDK1, CDK2, p38 and VEGFR-2.	25 mg	$20
410-09	Motesanib	AMG-706	Motesanib administered small molecule antagonist of VEGF receptors, platelet-derived growth factor receptors, and stem cell factor receptors.	10 mg	$178
410-10	MP-470	Amuvatinib	MP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Met, c-Kit, PDGFRa, Flt3	10 mg	$510
410-11	Nilotinib	AMN107 Tasigna	AMN107 inhibited the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values < 12 nM.	25 mg	$35
410-12	OSI-906		OSI-906 is a selective and orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R).	5 mg	$175
410-13	Pazopanib	GW-786034 Votrient	Pazopanib showed good potency against all the human VEGFR receptors with an IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.	25 mg	$75
410-14	Saracatinib	AZD0530	AZD0530 is highly selective for Src and Abl kinases against a large range of kinases (VEGFR2, FGFR, c-Kit, Aur-3 etc. > 5 µM).	10 mg	$65
410-15	Sorafenib	Nexavar BAY 43-9006	Sorafenib is an inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.	500 mg	$80
410-16	Sunitinib	Sutent SU-11248	SU11248 inhibited FLT3-ITD phosphorylation, VEGF- and FGF-induced proliferation of HUVECs and PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRα or PDGFRβ	100 mg	$30
410-17	Tandutinib	MLN518 CT53518	tandutinib inhibited FLT3 ,PDGFR, and KIT, IL-3-independent growth and FLT3-ITD auto-phosphorylation, and proliferation of human leukemia cell lines containing FLT3-ITD mutations	25 mg	$58
410-18	Tozasertib	VX-680 MK-0457	VX-680 is an inhibitor of Aurora-A,-B and -C kinases with apparent inhibition constant values of 0.6, 18, 4.6 nM respectively.	10 mg	$48
410-19	Vandetanib	Zactima ZD6474	Vandetanib is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor. It significantly prolonged the time to metastasis in an intravenous model of TKKK metastasis.	25 mg	$64
410-20	Vatalanib	PTK-787 ZK-222584 CGP79787D	PTK787/ZK 222584 inhibits the VEGF-induced phosphorylation	25 mg	$48

Diabetes and metabolic diseases

Catalog Number	Product Name	Function	Standard Size	Price
001-16	AdipRon	Producing effects similar to adiponectin in muscle and liver, such as activation of AMPK and PPAR-α pathways, and ameliorated insulin resistance and glucose intolerance in mice. It can also shifts the physiological profile of mice fed excess calories towards that of mice on a standard diet, but also modulates longevity pathways to prolong lifespan in mice.	1 mg	$80
001-17	IDE inhibitor 6bK	To regulates the abundance and signalling of glucagon and amylin, in addition to that of insulin. Under physiological conditions that augment insulin and amylin levels, such as oral glucose administration, acute IDE inhibition leads to substantially improved glucose tolerance and slower gastric emptying.	0.5 mg	$250
001-18	GLP-1 enhancer N55	Enhance GLP-1-dependent cAMP production and GLP-1R endocytosis in a dose-dependent and saturable manner.	100 µg	$300
032-51	OEA (Oleoylethanolamide)	OEA is an endogenous bioactive lipid-derived factor able to inhibited food intake and regulate glucose by activation of PPAR-alpha & GPR119	1 mg	$50
080-58A	XAV-939	XAV-939 specifically inhibits tankyrase PARP activity and selectively inhibits Wnt/β-catenin-mediated transcription.	2 mg	$59
080-57A	IWP-2	A small molecular produce mediated disruption of Wnt dependent signaling pathway	2 mg	$62
080-56A	CHIR99021	glycogen synthase kinase 3 (GSK3) inhibitor with IC50 less than 10 nM. Compared to other GSK-3 inhibitors, CHIR-99201 does not exhibit cross-reactivity against cyclin-dependent kinases CDKs) with 350-fold selectivity toward GSK-3compared to CDKs.	2 mg	$93